Compare Fastly Inc (FSLY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastly Inc vs Novartis AG — how do they compare? Fastly Inc trades at $28.85 (market cap $4.42B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 67.5× Fastly Inc's market cap, and Novartis AG pays a 3.02% dividend while Fastly Inc pays none. Which is the better fit depends on your goals.
| FSLY | NVS | |
|---|---|---|
Market Cap | $4.42B | $298.18B |
Sector | Technology | Health |
52-Week High | $33.50 | $168.62 |
52-Week Low | $6.85 | $119.31 |
Enterprise Value | $4.48B | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastly (FSLY) trades at $22.96, up 1.23% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $624 million in 2025, and the net loss margin improved to -19.5%. Recent news highlights security expansion and AI demand driving growth, with the stock surging 21% to $27.69 on August 10, 2026, per 24/7 Wall Street. The company raised its full-year 2026 outlook after Q2 results.
The outlook is positive with raised guidance and analyst consensus target of $28.25, but risks include persistent net losses, high debt, and competitive pressure. Investment opportunity lies in AI and security growth, yet profitability challenges and insider selling warrant caution for stock investors.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
